<DOC>
	<DOCNO>NCT00028314</DOCNO>
	<brief_summary>The goal study find fat waste weight loss arm legs HIV patient take highly active antiretroviral therapy ( HAART ) cause nucleoside/nucleotide reverse transcriptase inhibitor ( NRTIs ) waste reverse NRTI stop replace anti-HIV drug .</brief_summary>
	<brief_title>Effects Treatment Changes Fat Wasting Arms Legs HIV Patients</brief_title>
	<detailed_description>Recent study suggest body shape change , fat redistribution , fat lipoatrophy may relate NRTI component patient ' HAART protease inhibitor ( PI ) component . The hypothesis study thymidine analogue stavudine ( d4T ) zidovudine ( ZDV ) cause lipoatrophy non-thymidine analogue removal thymidine analogue HAART patient define lipoatrophy reverse process . In Step 1 , patient undergo axial mid-thigh abdomen computer tomography ( CT ) scan . If CT scan readable , patient restrictively randomly assign 1 2 treatment arm Step 2 . Patients Arm A-1 replace thymidine analogue component ( stavudine [ d4T ] zidovudine [ ZDV ] ) HAART abacavir ( ABC ) . Patients Arm B-1 discontinue current HAART receive PI nonnucleoside reverse transcriptase inhibitor ( NNRTI ) , either lopinavir/ritonavir ( LPV/r ) nevirapine ( NVP ) atazanavir , ritonavir , NVP . Patients currently efavirenz ( EFV ) provide study may choose continue EFV instead switch NVP . Comparisons make baseline value subcutaneous fat measure mid-thigh abdominal CT . Patients Arms A-1 B-1 remain study total 48 week advance Step 3 . Two additional group ( Arms A-2 B-2 ) make change HAART 28 week evaluate natural history change lipoatrophy time ; accrual group Step 3 discontinue . At Week 28 , patient Arms A-2 B-2 register Step 3 switch HAART designate new treatment . Arm A-2 patient replace d4T ZDV ABC 48 week . Arm B-2 patient replace HAART LPV/r plus NVP 48 week . If patient Arms A-2 B-2 complete 28-week delay switch regimen , enter Step 4 reregistered Arms A-1 B-1 , respectively , remain treatment assignment 48 week . If patient Arms A-2 B-2 already switch regimen , continue new regimen Week 76 .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Lipodystrophy</mesh_term>
	<mesh_term>Cachexia</mesh_term>
	<mesh_term>Wasting Syndrome</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Lopinavir</mesh_term>
	<mesh_term>Atazanavir Sulfate</mesh_term>
	<mesh_term>Nevirapine</mesh_term>
	<mesh_term>Abacavir</mesh_term>
	<criteria>Note : accrual Arms A2 B2 study discontinue . Inclusion Criteria Step 1 HIV infect Experiencing loss fat since start antiHIV therapy , especially arm legs Receiving antiHIV therapy 3 drug , include either stavudine zidovudine , 24 week prior study screen Viral load le 500 copies/ml study screen within 60 day prior study entry CD4 count 100 cells/mm3 obtain within 60 day prior study entry Approved method contraception Written inform consent Exclusion Criteria Step 1 Currently receive abacavir sulfate receive abacavir sulfate past AND following : unable tolerate lopinavir/ritonavir ( LPV/r ) nevirapine ( NVP ) ; fail antiHIV treatment contain LPV/r , 2 PIs , NNRTI ; take lamivudine ( 3TC ) tenofovir disoproxil fumarate ( TDF ) hepatitis B virus infection need remain 3TC TDFcontaining regimen ; low chance response LPV/r plus NVP Cancer treatment 6 month prior study entry Initiated oral drug low blood sugar level 24 week prior study entry . Patients take oral drug low blood sugar level 24 week prior study entry eligible . Began therapy male sex hormones 24 week prior study entry . Patients continuous , stable therapy male sex hormones 24 week prior study entry eligible . Certain medication within 14 day prior study entry Serious illness within 14 day prior study entry Hepatitis within 60 day prior study entry Thyroid problem Drug alcohol use , opinion investigator , would interfere study Currently use experimental agent except approve study Pregnant breastfeeding</criteria>
	<gender>All</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2013</verification_date>
	<keyword>HIV-1</keyword>
	<keyword>Abacavir</keyword>
	<keyword>Nevirapine</keyword>
	<keyword>Ritonavir</keyword>
	<keyword>RNA , Viral</keyword>
	<keyword>HIV Protease Inhibitors</keyword>
	<keyword>Reverse Transcriptase Inhibitors</keyword>
	<keyword>Anti-HIV Agents</keyword>
	<keyword>Viral Load</keyword>
	<keyword>HIV Wasting Syndrome</keyword>
	<keyword>ABT 378</keyword>
	<keyword>Treatment Experienced</keyword>
</DOC>